SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
S&P 500   3,639.66 (-2.80%)
DOW   29,296.79 (-2.11%)
QQQ   269.10 (-3.81%)
AAPL   140.09 (-3.67%)
MSFT   234.24 (-5.09%)
META   133.45 (-4.04%)
GOOGL   98.68 (-2.70%)
AMZN   114.56 (-4.77%)
TSLA   223.07 (-6.32%)
NVDA   120.76 (-8.03%)
NIO   13.76 (-6.84%)
BABA   81.24 (-3.65%)
AMD   58.44 (-13.87%)
T   14.94 (-2.48%)
MU   52.91 (-3.13%)
CGC   2.79 (-25.60%)
F   12.20 (-1.29%)
GE   64.56 (-2.51%)
DIS   97.16 (-2.88%)
AMC   6.53 (-8.29%)
PYPL   90.17 (-4.50%)
PFE   42.32 (-1.79%)
NFLX   224.75 (-6.36%)
NASDAQ:OCX

OncoCyte - OCX Stock Forecast, Price & News

$0.73
-0.01 (-1.36%)
(As of 10/7/2022 05:12 PM ET)
Add
Compare
Today's Range
$0.72
$0.75
50-Day Range
$0.71
$0.99
52-Week Range
$0.68
$3.73
Volume
106,009 shs
Average Volume
457,638 shs
Market Capitalization
$86.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.94

OncoCyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
300.2% Upside
$2.94 Price Target
Short Interest
Healthy
2.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.97mentions of OncoCyte in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$65,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.42) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

305th out of 1,075 stocks

Diagnostic Substances Industry

7th out of 15 stocks

OCX stock logo

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Brokerages Set OncoCyte Co. (NASDAQ:OCX) Price Target at $2.90
Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Oncocyte Announces Five-Year VA Contract for DetermaRx
Thursday 8/18 Insider Buying Report: FOX, OCX
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Company Calendar

Last Earnings
8/10/2022
Today
10/07/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.94
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+302.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-64,100,000.00
Net Margins
-846.58%
Pretax Margin
-845.37%

Debt

Sales & Book Value

Annual Sales
$7.73 million
Book Value
$0.71 per share

Miscellaneous

Free Float
113,793,000
Market Cap
$86.58 million
Optionable
Optionable
Beta
1.70

Key Executives

  • Mr. Ronald A. Andrews Jr. (Age 62)
    CEO & Director
    Comp: $801.84k
  • Mr. Mitchell S. Levine (Age 62)
    Corp. Devel. Officer
    Comp: $480.71k
  • Dr. Douglas T. Ross M.D. (Age 62)
    Ph.D., Chief Science Officer
    Comp: $558.94k
  • Ms. Gisela A. Paulsen (Age 56)
    COO & Pres
  • Mr. Anish John (Age 52)
    Chief Financial Officer
  • Dr. Ekkehard Schutz M.D.
    Ph.D., Chief Technology Officer
  • Mr. William Annett (Age 68)
    Advisor
  • Ms. Padma Sundar (Age 48)
    Chief Commercial Officer
  • Mr. Robert S. Seitz (Age 58)
    Head of Immune Oncology
  • Dr. Michael D. West Ph.D. (Age 69)
    Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.













OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCX shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price forecast for 2022?

5 equities research analysts have issued 12 month price targets for OncoCyte's stock. Their OCX share price forecasts range from $1.50 to $5.00. On average, they predict the company's share price to reach $2.94 in the next twelve months. This suggests a possible upside of 302.7% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2022?

OncoCyte's stock was trading at $1.89 on January 1st, 2022. Since then, OCX shares have decreased by 61.4% and is now trading at $0.73.
View the best growth stocks for 2022 here
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our OCX earnings forecast
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $2.50 million. OncoCyte had a negative net margin of 846.58% and a negative trailing twelve-month return on equity of 54.28%.

What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $0.73.

How much money does OncoCyte make?

OncoCyte (NASDAQ:OCX) has a market capitalization of $86.59 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at 949 409 7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.